| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCD-057 | n-Butylidenephthalide | >98%,Standard References |
|
| DC9281 | 1-NA-PP1 Featured | 1-Naphthyl PP1(1-NA-PP 1) is a selective inhibitor of src family kinases v-Src and c-Fyn as well as the tyrosine kinase c-Abl (IC50 values are 1.0, 0.6, 0.6, 18 and 22 μM for v-Src, c-Fyn, c-Abl, CDK2 and CAMK II respectively). |
|
| DC10889 | 1-NA-PP 1 hydrochloride Featured | 1-Naphthyl PP1(1-NA-PP1) is a selective inhibitor of src family kinases v-Src and c-Fyn as well as the tyrosine kinase c-Abl. |
|
| DC10215 | 7,8-Dihydroxyflavone | 7,8-Dihydroxyflavone acts as a potent and selective small-molecule agonist of the TrkB receptor (Kd ≈ 320 nM), the main signaling receptor of brain-derived neurotrophic factor (BDNF). |
|
| DC11707 | MDVN-1003 | A first-in-class, selective, orally bioavailable, dual inhibitor of BTK and PI3Kδ kinases with IC50 of 32.3 nM and 16.9 nM, respectively. |
|
| DC11612 | KBP-7018 hydrochloride | A novel potent, multikinase inhibitor with IC50 of 10, 7.6 and 25 nM for c-Kit, RET and PDGFRβ, respectively. |
|
| DC11611 | KBP-7018 | A novel potent, multikinase inhibitor with IC50 of 10, 7.6 and 25 nM for c-Kit, RET and PDGFRβ, respectively. |
|
| DC11916 | FD-5180 Featured | A novel protein kinase affinity probe... |
|
| DC11954 | JP-153 Featured | JP-153 (JP153) is a novel small molecule targets the Src-FAK-Paxillin signaling, inhibits Src-dependent phosphorylation of paxillin (Y118) and downstream activation of Akt (S473) in RECs; potently inhibits VEGF-induced proliferation and migration, inhibits retinal neovascularization in the murine oxygen-induced retinopathy model. |
|
| DC11804 | IQS-019 | A novel, potent inhibitor of most upstream tyrosine kinases in BCR signaling pathway, inhibits BCR kinases Lyn, Syk and Btk with IC50 of 0.15 uM, 1.6 uM and 2.1 uM, respectively. |
|
| DC11805 | IQS-019 mesylate | A novel, potent inhibitor of most upstream tyrosine kinases in BCR signaling pathway, inhibits BCR kinases Lyn, Syk and Btk with IC50 of 0.15 uM, 1.6 uM and 2.1 uM, respectively. |
|
| DC12007 | SOMG-833 | A potent, selective, ATP-competitive c-MET inhibitor with IC50 of 0.93 nM. |
|
| DC11721 | PF-06747775 | A potent, selective, irreversible EGFR mutants with IC50 of 12, 3, 4 and 5 nM for EGFR L858R-T790M, Del-T790M, L858R, and EGFR Del, respectively. |
|
| DC10922 | AAE871 | AAE871 (AAE-871) is a potent type I kinase inhibitor of FLT3 with IC50 of 34 nM, potently inhibits proliferation of FLT3-ITD- and D835Y-expressing cells (IC50<10 nM) through selective inhibition of FLT3 kinase activity.. |
|
| DC4231 | Linifanib (ABT-869) Featured | ABT-869 is an ATP-competitive, multi-targeted RTK inhibitor that is completely effective against all members of the vascular endothelial growth factor (VEGF) and platelet derived growth factor (PDGF) receptor families. |
|
| DC9660 | Acalabrutinib(ACP196) Featured | Acalabrutinib (ACP-196) is a second-generation, selective, irreversible inhibitor of BTK. |
|
| DC11512 | Acrizanib Featured | Acrizanib（LHA510） is a potent and selective angiogenesis inhibitor and VEGFR‑2 Inhibitor Specifically Designed for Topical Ocular Delivery, as a Therapy for Neovascular Age-Related Macular Degeneration. |
|
| DC10633 | AD80 Featured | AD80, a multikinase inhibitor, shows strong activity against human RET, BRAF, S6K, and SRC but were much less active than either AD57 or AD58 against mTOR. The IC50 value for RET is 4 nM. |
|
| DC5113 | AEE-788 (NVP-AEE788) Featured | AEE788 is a potent inhibitor of EGFR and HER2/ErbB2 with IC50 of 2 nM and 6 nM, less potent to VEGFR2/KDR, c-Abl, c-Src, and Flt-1, does not inhibit Ins-R, IGF-1R, PKCα and CDK1. Phase 1/2. |
|
| DC3164 | BIBW2992-MA2 (Afatinib dimaleate) Featured | Afatinib is an irreversible EGFR/HER2 inhibitor with an IC50 of 14 nM for in vitro potency against HER2. |
|
| DC10589 | AG 1406 Featured | AG 1406 is a selective inhibitor of the receptor tyrosine kinase VEGF receptor 2 . |
|
| DC8079 | AG-1557 Featured | AG-1557 is an ultra-potent inhibitor of epidermal growth factor receptor tyrosine kinase (EGFRK). |
|
| DC1080 | Tyrphostin 9（AG-17） Featured | AG-17 is an inhibitor of epidermal growth factor (EGF) receptor kinase with an IC50 value of 460 µM in the human epidermoid carcinoma cell line A431. |
|
| DC12382 | AG-99 Featured | AG-99 is an inhibitor of EGF receptor kinase with an IC50 value of 10 µM in the human epidermoid carcinoma cell line A431. |
|
| DC9330 | AIM-100 Featured | AIM-100 is a small molecule inhibitor of Ack1 with an IC50 of 24 nM IC50 value: 24 nM [3] Target: Ack1 Ack1 inhibitor AIM-100 not only inhibited Ack1 activation but also suppressed AKT tyrosine phosphorylation, leading to cell cycle arrest in the G1 ph |
|
| DC12072 | Alflutinib (AST2818 mesylate) Featured | Alflutinib (AST-2818, ASK120067) is a third generation EGFR mutation selective tyrosine kinase inhibitor, inhibits EGFR active mutations as well as T790M acquired resistant mutation.. |
|
| DC11495 | Allitinib Featured | Allitinib (AST-1306, ALS1306)) is a novel potent, selective irreversible EGFR and HER2 inhibitor with IC50 of 0.5 and 3 nM in cell-free assays. |
|
| DC11931 | Alofanib Featured | Alofanib ((RPT-835) is a potent, selective, allosteric FGFR2 inhibitor that significantly inhibits bFGF-induced proliferation of HUVEC cells with IC50 of 11 nM |
|
| DC8072 | Altiratinib(DCC-2701) Featured | Altiratinib is a MET/TIE2/VEGFR2/TRK (A,B,C) kinase inhibitor in Phase 1 clinical development for the treatment of invasive solid tumors including glioblastoma. |
|
| DC10209 | ALW-II-41-27 Featured | ALW-II-41-27 is a novel Eph receptor tyrosine kinase inhibitor, used for cancer treatment. |
|
